🇺🇸United States·April 08, 2026·daily

Dow Jones 30 Stocks SEC Filings — April 08, 2026

Across 50 SEC filings from Dow Jones 30-related entities on April 8, 2026, dominant themes include a proxy season surge with 15+ DEF 14A/DEFA14A filings for May 2026 AGMs, robust M&A activity (e.g., Clearwater sale process, Kenvue-Kimberly-Clark merger, CECO-Thermon), and mixed financial trends: explosive energy growth (Venture Global revenue +177% YoY to $13.8B) offset by consumer/healthcare softness (Kenvue sales -2.1% YoY, Avalyn losses +71% YoY to $85.2M). Institutional 13F-HR filings (12 total) reveal persistent heavy allocations to tech giants (Apple, Amazon, NVIDIA across 8+ filers) and ETFs, signaling broad market conviction in megacaps amid volatility. Capital allocation leans shareholder-friendly with buybacks (Voya $300M in Q1/Q2 2026, Intel $14.2B JV repurchase), while operational wins like Brookdale occupancy +250bps YoY to 82.0% highlight recovery plays. Portfolio-level trends show margin resilience (Kenvue op margin +410bps to 16.0%) despite top-line pressures, with forward catalysts clustered in H2 2026 mergers and May AGMs. Overall, blue-chip stability persists, but M&A and energy outliers offer alpha amid Nasdaq compliance risks in small-caps.

18 high priority32 medium50 total filings

🇺🇸United States·April 08, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 08, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (despite diverse inclusions like SPACs, financials, and energy), key themes include mixed financial performance with revenue growth in retail (e.g., PriceSmart +9.8% YoY six months, Ingles +6.6% Q1 FY2026) offset by operational declines (Harbor Diversified RPMs -20.1% YoY) and widening losses (SmartKem net loss despite +750% revenue, Franklin Covey Q1 loss widened to $2.0M). Proxy battles and annual meetings dominate (15+ DEF/DEFA14A filings), signaling governance focus amid May 2026 catalysts, while M&A activity shines (Fifth Era SPAC merger with Miotal, Corebridge-Equitable all-stock deal targeting YE2026 close). Capital allocation leans shareholder-friendly (Voya $300M buybacks Q1-Q2 2026, Rexford $250M repurchases), but cash burn risks persist (SmartKem cash -95% to $374k). Institutional 13F snapshots (10+ filings) show heavy ETF/tech tilts with no major shifts. Forward catalysts cluster in May 2026 AGMs/earnings, with positive sentiment in 20% of filings driving outperformance potential in retail/restaurants vs sector drags in airlines/transport.

26 high priority24 medium50 total filings

🇺🇸United States·April 08, 2026·daily

S&P 500 Healthcare Sector SEC Filings — April 08, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, healthcare-specific insights dominate with positive biotech momentum from Ensysce's $20M funding commitment, TuHURA's Kineta acquisition and $12.6M raise, Precision BioSciences' 115% scorecard attainment and $75M cash extension to 2028, Castle Biosciences' $344M 2025 revenue exceeding guidance with 37% YoY test volume growth, and Merck's $70B pipeline opportunity by mid-2030s (up $20B YoY) amid multiple FDA approvals. Contrasting this, Regeneron flagged a $102M Q1 2026 IPR&D charge impacting EPS by -$0.81, signaling acquisition-related costs. Proxy statements proliferate for May 2026 AGMs (Merck May 26, Castle May 28), highlighting strong pay-vs-performance and board elections. Institutional 13Fs (e.g., Civilization Ventures' $52M Natera, $90M BillionToOne; Lynch's $21M J&J) indicate sustained healthcare allocations amid diversified portfolios. Non-healthcare filings (financials, advisors) show buyback trends (Voya $300M total, Chewy $500M increase) and M&A (Corebridge-Equitable), but healthcare trends point to growth in diagnostics/biotech offset by one-off charges, with no broad margin compression or insider selling patterns.

18 high priority32 medium50 total filings

🇺🇸United States·April 07, 2026·daily

S&P 500 Technology Sector SEC Filings — April 07, 2026

Across the 10 filings in the USA S&P 500 Technology intelligence stream, governance and proxy-related disclosures dominate (5/10 filings), highlighting heightened shareholder activism and board defenses amid sector pressures. Period-over-period trends are sparse but stark in Aditxt's acquisition of Ignite Proteomics, where net losses widened 154% YoY to $5.7M, revenues plunged 40% to $43.5k, assets dropped 76% to $257k, and liabilities tripled to $7.1M, raising integration risks. Leadership transitions show stability with PSQ's seamless CFO handover and QumulusAI's stabilized exec team post-multiple changes, contrasting Aditxt's troubled M&A. Mixed sentiments prevail (e.g., Genco's proxy battle rejecting $23.50/share takeover), with neutral routine updates in CDCC, FHLB bonds, and bank filings; overall, low sector-wide growth signals but opportunities in IPO prep (QumulusAI) and financial structure shifts (Chemung). Critical implications include monitoring May 2026 AGMs for voting outcomes and takeover escalations, as capital allocation remains defensive with no dividend/buyback accelerations noted. Portfolio-level pattern: 40% of filings flag governance catalysts, potentially driving volatility in tech-adjacent names.

3 high priority7 medium10 total filings

🇺🇸United States·April 07, 2026·daily

Nasdaq 100 Stocks SEC Filings — April 07, 2026

Across 14 filings from NASDAQ-100 related entities, dominant themes include the onset of 2026 proxy season with multiple annual meetings clustered in May (Camden May 8, PayPal May 19, First Community May 20), highlighting governance votes, exec comp approvals, and director elections amid post-merger adjustments and proxy contests. Period-over-period trends show stark contrasts: PayPal's robust 2025 growth (TPV +7% YoY to $1.79T, revenues +4% to $33.2B, non-GAAP EPS +14% to $5.31, $6B buybacks) versus Aditxt's acquired Ignite Proteomics' deteriorating metrics (net loss widened to $5.7M from $2.2M YoY, revenues -40% to $43.5K, assets -76% to $257K, liabilities +3x to $7.1M with going concern doubts). Capital allocation leans shareholder-friendly in PayPal ($6.4B cash flow matched by repurchases), while M&A reveals risks (Aditxt impairment) and defenses (Genco rejecting $23.50/share bid as undervalued). Mixed sentiments prevail in performance disclosures (PayPal branded checkout misses, CEO transition; CCC exec departures), with neutral routine updates elsewhere. Portfolio-level patterns signal monitoring proxy battles and May catalysts for volatility, favoring strong performers like PayPal amid sector governance focus.

4 high priority10 medium14 total filings

🇺🇸United States·April 07, 2026·daily

S&P 500 Financials Sector SEC Filings — April 07, 2026

The 50 filings from the USA S&P 500 Financials stream reveal a dominant proxy season theme with 20+ DEF 14A/DEFA14A filings scheduling annual/special meetings in May 2026, alongside bank M&A momentum (e.g., Flushing Financial/OceanFirst merger approvals at 97%+ support) and insurance positives (MetLife variable income $475-525M Q1 ahead of $1.6B FY guide). Period-over-period trends show mixed results: revenue growth averaging +3-4% YoY in reports like UniFirst (+3.4% Q2, +3.1% H1) and XPO ($8.16B FY25), but frequent margin compression (UniFirst op income -16.7% YoY Q2; CPI Aerostructures gross profit -38.7% YoY) and losses (APEX net loss -371% QoQ). Capital allocation leans toward buybacks (UniFirst $32.7M H1 vs $12.5M prior, up 161%) and debt for M&A (Brink’s $1.225B term loan for NCR Atleos; Four Corners $200M facility). SPAC activity surges with extensions (Legato), new IPOs (RRE Ventures 25M units), and combos (Teamshares/Live Oak Q2 close), while exec changes signal transitions (Mattel CCO promo, Protagenic CFO exit). No widespread insider selling/buying patterns, but MHC stakes (Pioneer 57%) indicate stability. Implications: Near-term catalysts in May meetings/M&A closings favor event-driven trades; deteriorating margins warrant caution in ops-heavy firms.

35 high priority15 medium50 total filings

🇺🇸United States·April 07, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — April 07, 2026

Across 49 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (though diverse with proxies, 8-Ks, and 13Fs spanning financials, healthcare, tech, and limited staples like CCEP), proxy season dominates with 15+ DEF 14A/DEFA14A filings scheduling May 2026 AGMs (e.g., Travelers May 20, Xcel May 20, Teladoc May 21), emphasizing governance, say-on-pay, and auditor ratifications amid neutral sentiment. Capital allocation trends positive in select names: CCEP repurchased 290k shares (avg $90+), Ellington declared $0.13 monthly dividend, J.P. Morgan REIT raised $69M via share issuance. Sparse period-over-period data shows resilience (Xcel 6.2% EPS CAGR 2005-2025, 5% dividend CAGR, 23 yrs increases; Teladoc 2025 revenue $2.5B, intl +12% YoY, members +9%), but biotechs flag distress (Cell Source going concern doubt). Leadership transitions smooth (Mattel CCO promo), M&A/divestitures add liquidity (CVD $16.9M SDC sale), SPACs/IPOs active (KPET $200M IPO despite deficit). Portfolio-level: neutral-to-positive sentiment (12 positive, 24 neutral, 4 negative), low YoY trends but May catalysts loom for votes impacting comp/equity plans.

16 high priority33 medium49 total filings

🇺🇸United States·April 07, 2026·daily

S&P 500 Industrials Sector SEC Filings — April 07, 2026

Across 50 SEC filings primarily from diverse sectors misaligned with S&P 500 Industrials (heavy in biotech, finance, hospitality, and proxies), proxy season dominates with 25+ DEF 14A/DEFA14A filings scheduling virtual annual meetings in May 2026, highlighting governance, director elections, and say-on-pay votes amid mixed 2025 performance recaps. Period-over-period trends show revenue resilience (e.g., Collegium + record $780.6M, Tandem ~$1.015B surpassing $1B milestone + significant YoY growth, Global Net Lease AFFO $0.99/share exceeding guidance) but pockets of weakness (Phoenix Education Q2 rev -0.4% YoY, net income -33% YoY; 6-mo net income -58% YoY despite Adj EBITDA +7.4% YoY). Biotech financing surges positively (Opus $155M non-dilutive to extend runway to 2029, Kiora $24M placement), contrasted by Luminar Technologies' confirmed Chapter 11 liquidation (negative for lidar/auto supply chain). Capital allocation leans shareholder-friendly (Phoenix $0.21/share div + $50M buyback, Collegium $25M repurchases + $980M facility, Global Net Lease $2.2B debt reduction), with limited insider activity but strong management voting intent (e.g., Legato insiders for SPAC extension). Forward-looking catalysts cluster in mid-2026 (Opus topline data, INOVIO PDUFA Oct 2026), signaling alpha in turnarounds and M&A amid neutral-to-positive sentiment (18 positive, 24 neutral, 4 negative, 4 mixed). Portfolio-level implication: Favor biotech/healthcare proxies with growth beats and financings over pure industrials voids, watch May proxy outcomes for governance shifts.

24 high priority26 medium50 total filings

🇺🇸United States·April 07, 2026·daily

S&P 500 Energy Sector SEC Filings — April 07, 2026

Across the 7 filings in the S&P 500 Energy stream, dominant themes include proxy preparations for 2026 annual meetings at Chevron (CVX) and Cheniere Energy (LNG), with Cheniere highlighting exceptional 2025 results (Net Income >$5.3B, Distributable Cash Flow ~$5.3B, no declines noted). Chevron filings emphasize Hess Corp. acquisition integration (completed July 18, 2025, with John B. Hess joining board), board recommendations FOR directors/auditors/compensation but AGAINST governance proposals, signaling stable leadership amid M&A. Neutral sentiment prevails in Chevron's multiple DEFA14A/DEF 14A (materiality 3-7/10), contrasted by positive tones at Cheniere (8/10) and Stoke Therapeutics (6/10), though non-energy filings like Copper Property (neutral, store disclosures) and Stoke (board addition) dilute sector focus. No explicit YoY/QoQ trends across most, but Cheniere's 'outstanding' 2025 metrics imply strong period-over-period growth; no insider trading, capital allocation, or M&A valuations detailed beyond Hess completion. Key implication: Near-term catalysts from May 2026 AGMs could affirm management conviction, with Cheniere's cash flow supporting returns amid energy transition scrutiny. Portfolio trend: Governance battles highlight ESG risks, but financial strength in LNG (Cheniere) positions energy leaders for upside.

3 high priority4 medium7 total filings

🇺🇸United States·April 07, 2026·daily

Dow Jones 30 Stocks SEC Filings — April 07, 2026

The 50 filings for the USA Dow Jones 30 intelligence stream reveal a dominant proxy season theme, with over 25 DEF 14A/DEFA14A filings scheduling virtual annual meetings in mid-May 2026 (e.g., May 19-21), focusing on director elections, auditor ratifications, say-on-pay votes, and plan approvals amid neutral sentiment in most cases. Period-over-period trends show stark contrasts: robust growth in Bread Financial Holdings (net income +87% YoY to $521M, EPS +98% to $10.96), EVERTEC (record 2025 revenue, Latin America expansion), and Global Net Lease (AFFO $0.99/share exceeding guidance, 32% TSR vs peers); offset by collapses like Kaixin Holdings (revenues $31.5M in 2023 to $0 in 2024, losses to $53.9M in 2025) and Phoenix Education (Q2 revenue -0.4% YoY, net income -33% YoY). Capital allocation leans shareholder-friendly with dividends/buybacks (Phoenix $0.21/share div + $50M repurchase; Global Net Lease repurchases amid $2.2B debt cut), while M&A/divestitures provide liquidity (CVD $16.9M SDC sale netting $15M; PROG/P-Squared acquisition). Positive biotech catalysts like Nuvalent's NDA submission contrast liquidity risks (Inotiv covenant waiver). No widespread insider selling/buying patterns, but equity awards signal alignment (Envista CEO 696k shares). Overall, financials/REITs show resilience, biotechs/SPACs offer upside, but select operational distress demands caution.

25 high priority25 medium50 total filings

🇺🇸United States·April 07, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 07, 2026

Across 50 SEC filings from S&P 500 Consumer Discretionary and related sectors, proxy statements dominate (over 25 DEF 14A/DEFA14A) signaling peak annual meeting season in May 2026, with neutral sentiment but emphasis on governance, director elections, and say-on-pay votes. Period-over-period trends show mixed revenue growth (e.g., UniFirst +3.4% YoY Q2, Jefferies +16.1% YoY) offset by widespread margin compression (UniFirst op income -16.7% YoY, CPI Aerostructures gross profit -38.7% YoY) and operational losses (FG Nexus $40-45M Q1 loss, Skillsoft net loss margin -27.3%). Capital allocation leans shareholder-friendly with buybacks (FG Nexus 2.2M shares at $16.04 avg, UniFirst $32.7M H1) and new debt facilities (Four Corners $200M term loan for Q2/Q3 acquisitions). Mergers advance (Flushing/OceanFirst 97.3% approval) amid strategic reviews (Xponential Fitness exploring sale). Bullish highlights include Target Hospitality's $320.6M FY25 revenue/$0 net debt and Bread Financial's 87% YoY net income surge to $521M; risks from Nasdaq non-compliance (Hydrofarm) and auditor changes. Portfolio-level implication: Selective opportunities in resilient retail/hospitality amid margin pressures, monitor May catalysts for governance shifts.

26 high priority24 medium50 total filings

🇺🇸United States·April 07, 2026·daily

S&P 500 Healthcare Sector SEC Filings — April 07, 2026

Across the 50 filings in the USA S&P 500 Healthcare stream (with broader context from financials and biotechs), proxy season dominates with 20+ DEF 14A/DEFA14A filings scheduling May 2026 AGMs, emphasizing governance, director elections, say-on-pay (mixed support at Thermo Fisher), and auditor ratifications. Healthcare-specific trends show resilient large-cap performance (Amgen +10% YoY revenue, record 18 product sales) contrasted by small-cap biotech volatility: positive catalysts like Pulse Biosciences' pivotal trial enrollments and TriSalus CMO promotion, offset by Protagenic CFO exit and NovaBridge's 83% wider operating losses ($94.3M). Capital allocation remains shareholder-friendly with Amgen's $5B dividends/$6B debt reduction, Jackson Financial's 12.5% dividend hike/$1B buyback expansion, and Cintas' $933M repurchases amid 8.9% YoY revenue growth. Merger approvals (Flushing 97.3% yes, OceanFirst issuance approved) signal M&A momentum in adjacents, while Nasdaq compliance regains (Artelo, Tianci) aid biotechs. No major guidance cuts; forward catalysts cluster in May AGMs and clinical milestones (Pulse 6/12-month endpoints). Overall, bullish large-cap stability vs. high-beta biotech risks, with portfolio-level revenue growth averaging +10-16% YoY where reported, but margin pressures in mixed sentiment filings.

25 high priority25 medium50 total filings

🇺🇸United States·April 06, 2026·daily

S&P 500 Technology Sector SEC Filings — April 06, 2026

Across 17 filings from S&P 500 Technology and adjacent sectors, proxy season dominates with 10 DEF/DEFA14A filings signaling upcoming May 2026 annual meetings, featuring mixed executive comp outcomes and governance votes amid neutral sentiment. Core tech names like ServiceNow, Broadcom, Oracle, and CrowdStrike drive bullish themes with robust 2025 performance (e.g., ServiceNow's 21% YoY subscription revenue growth to $12.8B, 31% non-GAAP op margin), strategic AI deals extending to 2031, C-suite appointments during high-growth phases, and expanded $1.5B share repurchases. Period-over-period trends show strength in software/cloud (ServiceNow +31% total rev YoY, Rule of 56) contrasted by real estate proxies' mixed comp (MAA Core FFO beat but SS NOI miss -1.36% vs -1.15% target). Positive leadership changes at Oracle, Veradigm, and Murphy USA indicate stabilization/turnaround efforts, while Broadcom's Google TPU deal positions it for long-term AI compute dominance. Portfolio-level, 4/5 key tech filings bullish on growth/capital returns, but high debt in Madison Air ($3.98B, 68% of op cash flows) flags leverage risks; implications favor overweighting software leaders ahead of catalysts.

10 high priority7 medium17 total filings

🇺🇸United States·April 06, 2026·daily

Nasdaq 100 Stocks SEC Filings — April 06, 2026

Across 13 NASDAQ-100 related filings dated April 6, 2026, proxy season dominates with 7 DEF/DEFA14A filings highlighting annual meetings in May 2026, mixed executive compensation outcomes, and governance updates amid stable but unremarkable sentiment. Real estate firms like MAA and AvalonBay show mixed performance with MAA beating Core FFO ($8.77 vs $8.74 target) and FAD ($696M vs $685M) but missing SS NOI (-1.36% vs -1.15%) and 3-yr TSR (-1.47% vs 4.07%), while audit fees declined 13% YoY to $2.48M. Leadership transitions are positive, including permanent CFO appointments at Veradigm and Murphy USA, Cisco's board refresh, and Broadcom's blockbuster AI deals with Google (TPUs to 2031) and Anthropic (3.5GW capacity from 2027). Madison Air Solutions' S-1/A reveals sharp operating cash flow growth (+118% YoY to $480M) but high debt service ($549M, 68% of ops cash) and material control weaknesses pre-IPO. Portfolio-level trends include neutral-to-mixed sentiment (avg materiality 6.5/10), no insider trading signals, limited capital returns data, and a catalyst cluster of May shareholder meetings; implications favor monitoring real estate comp votes and AI supply chain momentum for near-term volatility.

8 high priority5 medium13 total filings

🇺🇸United States·April 06, 2026·daily

S&P 500 Financials Sector SEC Filings — April 06, 2026

Across 50 filings in the USA S&P 500 Financials intelligence stream (despite some cross-sector inclusions), dominant themes include a surge in proxy materials for May 2026 annual meetings (e.g., Schwab, MAA, Genworth, JPM), signaling routine governance but with positive comp approvals; robust M&A activity (Neurocrine-Soleno $2.9B, Profusa LOI $30M stock); mixed financial trends with JPM's record $185.6B revenue/17% ROE contrasting Airsculpt's -15.8% YoY revenue drop to $151.8M and widened net loss to -$11.7M; SPAC/IPO filings highlighting dilution risks. Period-over-period, 4/10 with revenue data show declines averaging -12% YoY (Airsculpt -15.8%, Laird +24% outlier), while JPM/Middlesex post strong growth; capital allocation leans to dividends (Middlesex 53-year streak) and buybacks absent. Forward-looking catalysts cluster in May meetings and Q2 deals, with guidance stable/positive (Airsculpt FY26 $151-157M revenue). Portfolio implication: Financials like JPM/Schwab exhibit strength amid sector proxy normalization, but watch M&A dilution and revenue softness in adjacent names.

25 high priority25 medium50 total filings

🇺🇸United States·April 06, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — April 06, 2026

Across 40 SEC filings in the USA S&P 500 Consumer Staples intelligence stream (encompassing food/beverage like Krispy Kreme/McCormick alongside broader market filings), key themes include widespread board refreshments and leadership transitions (12+ instances, e.g., Krispy Kreme adding Kraft Heinz alum, Tapestry Pinterest CTO), accelerating M&A (McCormick-Unilever SpinCo tax-free merger, Clear Channel Mubadala-backed deal), and mixed financial trends with average reported revenue growth of +5.8% YoY (iQSTEL +11.9% to $317M, NewtekOne volumes +7% implied, offset by Tsakos -0.7%, Elvictor +0.3%). Margin trends show slight improvement where noted (iQSTEL gross +72bps to 3.46%), but op ex pressures (Elvictor +19%). Forward-looking data clusters catalysts in late April-May 2026 (10+ AGMs/earnings). No major insider buys/sells, but separations (Krispy CPO, DeFi CCO) and capital allocation via share issuances/dilutive debt amendments (Bright Mountain 2.9M shares). Sentiment positive/neutral in 70%, mixed in 25%; actionable: Buy growth catalysts like NewtekOne, avoid debt restructurings. Portfolio implication: Staples governance strengthening amid modest growth, M&A upside for McCormick.

16 high priority24 medium40 total filings

🇺🇸United States·April 06, 2026·daily

S&P 500 Industrials Sector SEC Filings — April 06, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly including aerospace, machinery, and adjacent sectors), proxy statements dominate (over 60% of filings) signaling peak proxy season with clustered 2026 AGMs in mid-May, featuring director elections, say-on-pay, auditor ratifications, and equity plans amid mixed shareholder support (e.g., NioCorp's LTIP saw 5.3M against votes). Period-over-period trends reveal selective growth in industrials like Howmet Aerospace (sales +11.1% YoY to $8.25B, EBITDA +26.2%) and Integer Holdings (sales +8% YoY to $1.85B, adj EPS +21%), contrasted by energy headwinds (Phillips 66 Q1 MTM losses ~$900M) and deteriorations (Shepherd's net income -19% YoY, Nutra Pharma net loss -47.8% worse YoY despite sales +22.4%). Forward-looking catalysts include Q1 impacts (Biogen $34M IPRD expense hit EPS $0.19, Enphase GAAP margin -6.7pts from tax credit sale), M&A (Legence $427M Bowers acquisition boosting pro forma revenue to $3.45B), and capital actions (Horace Mann $57M returns via dividends/buybacks). Portfolio-level patterns show capital allocation favoring shareholder returns and tuck-ins, but rising expenses/expenses pressures in 7/15 quantified filings average margin hits of -150bps where noted; implications favor monitoring aerospace outperformance vs energy volatility for tactical positioning ahead of May catalysts.

27 high priority23 medium50 total filings

🇺🇸United States·April 06, 2026·daily

S&P 500 Energy Sector SEC Filings — April 06, 2026

Across 10 filings in the S&P 500 Energy stream (with some cross-sector context), proxy season kicks off with 7 DEF/DEFA14A filings highlighting annual meetings in May 2026, mixed executive comp performance (e.g., MAA beat Core FFO $8.77 vs $8.74 target but missed SS NOI -1.36% vs -1.15% and 3-yr TSR -1.47% vs 4.07%), and neutral governance updates. Energy pure-plays show divergence: Phillips 66 (PSX) flags severe Q1 2026 MTM losses of $900M across Refining ($350-450M), Marketing ($300-400M), and Renewables ($100-200M) due to commodity spikes and $3B collateral outflow, offset by strong Midstream $550-600M; Cheniere Energy (LNG) and Partners (CQP) signal leadership stability via transitions/appointments effective April-May 2026. Limited YoY/QoQ trends include MAA audit fees -13% to $2.48M and Copper CTL $0.081/unit distribution payable Apr 10; no broad insider selling/buying or M&A. Portfolio-level: Refining volatility pressures margins/debt (PSX net debt $22B, target $17B by 2027), while LNG/governance steady; implications include near-term refining downside risk but May catalysts for comp votes and board refresh.

4 high priority6 medium10 total filings

🇺🇸United States·April 06, 2026·daily

Dow Jones 30 Stocks SEC Filings — April 06, 2026

Across 50 SEC filings from Dow Jones 30 constituents and related entities on April 6, 2026, dominant themes include a surge in proxy materials (25+ DEF/DEFA14A filings) signaling peak annual meeting season in May 2026, with votes on directors, compensation, auditors, and equity plans; ongoing M&A and SPAC activity (Clear Channel merger, Inflection Point IPO, Spring Valley combo); leadership transitions (TVA CEO retirement, Veradigm CFO appointment, Cisco/Verizon board shifts); and debt restructurings/amendments (Clear Channel consents, Mativ Ninth Amendment, Honest Co. First Amendment). Period-over-period trends are sparse but highlight improvements like Horace Mann's core earnings up YoY to $195.8M (ROE +300bps to 12.4%), Madison Air operating cash flows +118% YoY to $480M, and Strategic Acquisitions net loss narrowed 67% YoY to $40k, contrasted by revenue drops (Strategic to $0) and cash plunges (-98%). Capital allocation shows shareholder returns (Horace Mann $57M divs/buybacks), equity grants (Oxbridge Re NEOs), and high debt service burdens (Madison Air 68% of cash flows). Positive regulatory tailwinds for digital assets (Evernorth XRP clarity) and fusion tech (Spring Valley) emerge, but risks from merger delays, financial strains (MSP Recovery advances), and control weaknesses (Madison Air) loom. Portfolio implications favor monitoring DJ30 names like JPM (record $185.6B revenue), Verizon/Cisco board changes for governance signals, with alpha in M&A catalysts amid neutral-to-mixed sentiment (60% neutral).

29 high priority21 medium50 total filings

🇺🇸United States·April 06, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 06, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (with cross-sector influences from financials and REITs impacting retail/auto/entertainment), proxy season dominates with 25+ DEF 14A/DEFA14A filings highlighting board refreshes (e.g., 50% new independents at Principal Financial), auditor ratifications, and stock incentive plan approvals signaling governance strength and capital allocation toward equity comp. M&A/divestiture activity is robust, including Profusa's $30M PanOmics LOI (closing by June 2026), Aptiv's Versigent spin-off (April 1, 2026), Six Flags' sale of 6 parks (April 6, 2026), and Laird Superfood's acquisition showing 24% YoY sales growth to $45.3M with net income turnaround to $1.6M. Where period comparisons exist, trends show revenue growth (avg +20% YoY in 3 cases) but mixed cash positions (e.g., Laird cash down to $0.16M). Leadership changes (e.g., Veradigm permanent CFO, Mawson board overhaul) indicate strategic pivots, while funding deals like PacifiCorp's $2.55B LC and Goldman Sachs indenture support expansion. Portfolio-level, positive sentiment in 12/50 (24%) vs mixed/neutral, with May 2026 overloaded with 20+ annual meetings as key catalysts; actionable theme is governance-driven stability amid M&A for consumer firms.

30 high priority20 medium50 total filings